How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer [ID1566]

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about nivolumab plus ipilimumab and chemotherapy

Marketing authorisation indication

2.1 Nivolumab (Opdivo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, Bristol-Myers Squibb) and 2 cycles of platinum-based chemotherapy has a marketing authorisation for 'the first-line treatment of metastatic non-small-cell lung cancer in adults whose tumours have no sensitising epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list price of nivolumab is £2,633 per 240 mg per 24-ml vial (excluding VAT; BNF online, accessed March 2021). The company has a commercial arrangement. This makes nivolumab available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

2.4 The list price of ipilimumab is £15,000 per 200 mg per 40-ml vial (excluding VAT; BNF online, accessed March 2021). The company has a commercial arrangement. This makes ipilimumab available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.